Solvonis CEO: Phase III is where the real value gets created

About this episode

Anthony Tennyson, CEO of Solvonis Therapeutics, discusses the company's strategic focus on CNS disorders and the value of advancing their lead program SVN-001 through Phase III trials.

Solvonis Therapeutics PLC (LSE:SVNS) CEO Anthony Tennyson tells Proactive's Stephen Gunnion that 2025 was a transformational year, marked by the acquisition of Awakn Life Sciences, a strategic rebrand, and a sharp refocus on high-burden CNS disorders. The centrepiece of the conversation is lead programme SVN-001 and the decision to take it through phase III rather than pursue an early licensing deal. Tennyson is direct about the rationale: shareholder value is greater at the end of a successful phase III than before it. Phase II data for SVN-001 in severe alcohol use disorder showed meaningfully improved sobriety outcomes, and the broader pipeline — including SVN-002 and early-stage asset SVN-015 — continues to advance across addiction and psychiatry. Tennyson also flags improving conditions in the US, with growing regulatory and investor support providing a useful tailwind for the sector. For more insights and updates on emerging biotech companies, visit Proactive’s YouTube channel, like this video, subscribe, and enable notifications so you never miss future content. #SolvonisTherapeutics #BiotechPipeline #CNSDisorders #DrugDevelopment #SVN001 #AlcoholUseDisorder…

People in this episode

Host: Stephen Gunnion

Guest: Anthony Tennyson

Topics covered

• biotech
• CNS disorders
• drug development
• investing
• clinical trials

Keywords

• Solvonis Therapeutics
• SVN-001
• CNS disorders
• biotech investing
• clinical trials
• alcohol use disorder
• drug development

Mentioned in this episode

Organizations: Solvonis Therapeutics PLC, Awakn Life Sciences

Products: SVN-001, SVN-002, SVN-015

Places: US

More episodes of Proactive - Interviews for investors

• Regan Capital CIO on bond market opportunities in a rising rate environment · June 12, 2026 · 6 min
• Light Science Technologies lifts capacity 50% with new SMT line and global client win · June 12, 2026 · 5 min
• Poolbeg Pharma launches POLB 001 TOPICAL trial to tackle CAR-T side effects · June 12, 2026 · 4 min
• Lumos Diagnostics expands FebriDx adoption across 100+ US healthcare sites with CLIA Waiver · June 11, 2026 · 8 min
• Flow Metals advances drill-ready Yukon gold project while expanding Copper exploration in B.C. · June 11, 2026 · 6 min
• Midstream energy sector positioned for growth as LNG and AI drive demand · June 11, 2026 · 7 min